Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
about
Deferasirox for managing transfusional iron overload in people with sickle cell diseasePharmacogenetic study of deferasirox, an iron chelating agentHow I manage cerebral vasculopathy in children with sickle cell disease.Organizing national responses for rare blood disorders: the Italian experience with sickle cell disease in childhood.Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.Deferasirox: appraisal of safety and efficacy in long-term therapy.Deferasirox: pharmacokinetics and clinical experience.Indications and complications of transfusions in sickle cell disease.Current approach to iron chelation in children.Clinical pharmacology of deferasirox.Deferasirox nephrotoxicity-the knowns and unknowns.Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia.How we manage iron overload in sickle cell patients.Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.L-mimosine and dimethyloxaloylglycine decrease plasminogen activation in periodontal fibroblasts.Long-term safety and efficacy of deferasirox in young pediatric patients with transfusional hemosiderosis: Results from a 5-year observational study (ENTRUST).Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.Effect of deferasirox chelation on liver iron and total body iron concentration.Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemiaTransient Elastography (TE) is a Useful Tool for Assessing the Response of Liver Iron Chelation in Sickle Cell Disease Patients
P2860
Q24194549-687DB12F-4700-4ED3-810E-86CA23B67BB9Q28533457-8FD5A052-8E3B-4EAA-8C8C-F50117B17080Q30945117-7E31EC8B-6F89-483D-AB38-552E3BFB458FQ34508200-D794D971-97F2-4032-9683-5EFF84E3579DQ35906193-F738DCA3-3DB4-4117-B713-DCE9290E878BQ36524624-C9CE2098-98B2-498B-9723-B277F48AED23Q37095523-54D8D622-BF59-4E66-BE5D-6196CFA0E0B6Q37969225-377A985A-0F15-407E-9A18-0F022A5287AEQ38008292-1FD04310-B0AD-440C-BD38-88FF8E50D6BEQ38197269-D9501C05-D177-46BC-A06F-C2EB56B4F2E8Q38226394-CEEA0F8D-6612-432A-AF60-A5522A2B20BEQ38232442-618FB8CC-D2EA-43D7-8BCD-7E0E7C0202A2Q38661953-1018E118-8FEE-4722-9E74-818406097357Q39179372-11A906EB-10EE-4840-9DB1-BDD5F3DFDD7CQ41432463-F41FEA18-A438-4E53-93B4-47557A548908Q42440906-BF8A9F67-7C82-47F1-8FA6-C4D1A3C48863Q44113037-4475B248-9594-4D55-8EB5-571B9A91E52BQ44645350-EE08772E-89CA-4CF1-B4E6-CC3700C2B4CAQ45150331-309815B6-6105-4F6B-BAA5-E8C011EB7332Q45392161-0B15A648-8F57-469D-948B-4BCB1C60503BQ47422490-1A3EC6BF-193B-4991-BE38-46A5C04AAD06Q56389520-83DBD480-5AC2-416A-A082-1D30248D7288Q58775572-6A4FFAB1-A0D4-4F16-9671-A7402C6ECBAB
P2860
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Long-term safety and efficacy ...... ents with sickle cell disease.
@ast
Long-term safety and efficacy ...... ents with sickle cell disease.
@en
type
label
Long-term safety and efficacy ...... ents with sickle cell disease.
@ast
Long-term safety and efficacy ...... ents with sickle cell disease.
@en
prefLabel
Long-term safety and efficacy ...... ents with sickle cell disease.
@ast
Long-term safety and efficacy ...... ents with sickle cell disease.
@en
P2093
P2860
P50
P1476
Long-term safety and efficacy ...... ents with sickle cell disease.
@en
P2093
Abdullah Kutlar
Cameron Tebbi
Felicia Wilson
Françoise Bernaudin
Gian Luca Forni
Kathryn Hassell
Liesl Mathias
Louis Griffel
Peter Lane
Renee Gardner
P2860
P304
P356
10.1111/J.1365-2141.2011.08720.X
P407
P577
2011-05-19T00:00:00Z